Article

Antidepressants Reduce the Effectiveness of Tamoxifen

Author(s):

Taking tamoxifen at the same time as certain drugs that treat depression and hot flashes may reduce the cancer drug’s ability to prevent breast cancer recurrence.

Taking tamoxifen at the same time as certain drugs that treat depression and hot flashes may reduce the cancer drug’s ability to prevent breast cancer recurrence. The offenders in the study—Paxil (paroxetine), Prozac (fluoxetine), and Zoloft (sertraline)—are part of a class of drugs that inhibit CYP2D6, an enzyme that converts tamoxifen to its active form.

A U.S study found that after two years, 7.5 percent of women who took only tamoxifen had a recurrence, compared with 16 percent who took Paxil, Prozac, or Zoloft—drugs considered to be the most potent CYP2D6 inhibitors. That difference translates to a 120 percent increase in the risk of breast cancer recurrence. Patients taking the so-called weaker antidepressants, Celexa (citalopram), Lexapro (escitalopram), and Luvox (fluvoxamine), did not have an increased risk of recurrence.

However, a Dutch study presented at the meeting did not find that simultaneous use was unsafe, most likely because of the small number of patients in the study who took both drugs, said Julie Gralow, MD, of the Seattle Cancer Care Alliance, at a press briefing. (Gralow was not involved in either study.) The Dutch trial included less than half the number of patients in the U.S. study who took the drugs concurrently—150 versus 353 women. Other drugs to treat depression and hot flashes that do not inhibit CYP2D6 should be considered for tamoxifen patients, said Gralow.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
Image of two doctors with text.
Imiage of two doctors with text.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
Image of woman.
Picture of Dr. Pouneh Razavi
Related Content